TOROMONT INDUSTRIES LTD CD (OTCMKTS:TMTNF) had an increase of 1.7% in short interest. TMTNF’s SI was 119,900 shares in February as released by FINRA. Its up 1.7% from 117,900 shares previously. With 1,400 avg volume, 86 days are for TOROMONT INDUSTRIES LTD CD (OTCMKTS:TMTNF)’s short sellers to cover TMTNF’s short positions. It closed at $42.6944 lastly. It is down 0.00% since February 19, 2017 and is . It has underperformed by 16.70% the S&P500.
Analysts expect vTv Therapeutics Inc. (NASDAQ:VTVT) to report $-0.42 EPS on February, 26.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.42 EPS. After having $-0.38 EPS previously, vTv Therapeutics Inc.’s analysts see 10.53% EPS growth. The stock increased 4.08% or $0.26 during the last trading session, reaching $6.63. About 73,637 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 0.20% since February 19, 2017 and is downtrending. It has underperformed by 16.90% the S&P500.
Toromont Industries Ltd. provides specialized capital equipment in Canada, the United States, and internationally. The company has market cap of $3.40 billion. It operates in two divisions, Equipment Group and CIMCO. It has a 26.26 P/E ratio. The Equipment Group segment is involved in the sale, rental, and service of mobile equipment for Caterpillar and other manufacturers; sale, rental, and service of engines used in a variety of applications, including industrial, commercial, marine, on-highway trucks, and power generation; and sale of complementary and related products, parts, and services.
Among 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. vTv Therapeutics Inc had 3 analyst reports since August 24, 2015 according to SRatingsIntel. Stifel Nicolaus initiated it with “Buy” rating and $17 target in Monday, August 24 report. Piper Jaffray initiated it with “Overweight” rating and $24 target in Monday, August 24 report. The company was initiated on Friday, September 4 by Canaccord Genuity.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $217.55 million. The company's drug candidate for the treatment of Alzheimer's disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.